Apixaban reduces hepatic decompensation in patients with cirrhosis (ApiHep): A randomized controlled trial

Background: Evolving data suggest that anticoagulation is safe in cirrhosis and may improve decompensation-free survival in select patients. This study aimed to assess the efficacy and safety of the direct oral anticoagulant apixaban in patients with cirrhosis. Methods: In this open-label randomized controlled trial with blinded endpoint assessment, adult patients (18–60y) with cirrhosis (Child-Pugh B7–C10) without splenoportal axis thrombosis were randomized (1:1) to receive apixaban (2.5 mg twice daily) along with standard medical therapy (SMT) or SMT alone for 12 months. The primary outcome was the comparison of the proportion of patients with hepatic decompensation at 1 year. Secondary outcomes included frequency of liver-related events, overall and liver-related mortality, and adverse events (AEs). Results: One hundred thirty-four patients (mean age 43.4±9.5 y; Child-Pugh B/C:115/19) were randomized (67 Apixaban+SMT and 67 SMT). Patients receiving apixaban experienced significantly lower rates of hepatic decompensation compared with SMT (33.1% vs. 54.3%; absolute risk reduction 21.2% [95% CI: 4.5%–38.2%]; p =0.013). Although rates of ascites (6.4% vs. 17.4%), HE (21.2% vs. 36.0%), and variceal bleeding (7.5% vs. 14.6%) were lower among patients receiving Apixaban+SMT as compared with SMT alone, the differences were not statistically significant. No significant between-group differences in all-cause and liver-related mortality at 1 year were noted. There were no significant between-group differences in AEs (55.2% vs. 53.7%), any bleeding (41.8% vs. 46.3%), and major bleeding (9.0% vs. 11.9%) events. Conclusions: Apixaban significantly reduced hepatic decompensation events without increasing hemorrhagic episodes in Child-Pugh B7-C10 cirrhosis (CTRI/2023/09/058018).

Authors

Institutions

Publication Details

Journal
Hepatology Communications
Published
2026-11-19
DOI
https://doi.org/10.1097/hc9.0000000000001088
Primary Topic
Liver Disease and Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Apixaban reduces hepatic decompensation in patients with cirrhosis (ApiHep): A randomized controlled trial

Shivanand Gamanagatti, Mukul Aggarwal, Ankur Goyal, Deepak Gunjan et al.
Hepatology Communications
Liver Disease and Transplantation
article

Apixaban reduces hepatic decompensation in patients with cirrhosis (ApiHep): A randomized controlled trial

Shivanand Gamanagatti, Mukul Aggarwal, Ankur Goyal, Deepak Gunjan, Samagra Agarwal, Baibaswata Nayak, Ashwani Kumar Mishra, Sagnik Biswas, Melissa Glenda Lewis, Jasmita Dass, Arnav Aggarwal, Sarthak Saxena, Viren Sardana, Raju Sharma, Vishal Singh Chauhan, S. Shalimar, Shekhar Swaroop, Shubham Jain, Ayush Agarwal, Ankit Agarwal, Soumya Jagannath Mahapatra, Amit Yadav, Sonu Kumar
article en

Abstract

Background: Evolving data suggest that anticoagulation is safe in cirrhosis and may improve decompensation-free survival in select patients. This study aimed to assess the efficacy and safety of the direct oral anticoagulant apixaban in patients with cirrhosis. Methods: In this open-label randomized controlled trial with blinded endpoint assessment, adult patients (18–60y) with cirrhosis (Child-Pugh B7–C10) without splenoportal axis thrombosis were randomized (1:1) to receive apixaban (2.5 mg twice daily) along with standard medical therapy (SMT) or SMT alone for 12 months. The primary outcome was the comparison of the proportion of patients with hepatic decompensation at 1 year. Secondary outcomes included frequency of liver-related events, overall and liver-related mortality, and adverse events (AEs). Results: One hundred thirty-four patients (mean age 43.4±9.5 y; Child-Pugh B/C:115/19) were randomized (67 Apixaban+SMT and 67 SMT). Patients receiving apixaban experienced significantly lower rates of hepatic decompensation compared with SMT (33.1% vs. 54.3%; absolute risk reduction 21.2% [95% CI: 4.5%–38.2%]; p =0.013). Although rates of ascites (6.4% vs. 17.4%), HE (21.2% vs. 36.0%), and variceal bleeding (7.5% vs. 14.6%) were lower among patients receiving Apixaban+SMT as compared with SMT alone, the differences were not statistically significant. No significant between-group differences in all-cause and liver-related mortality at 1 year were noted. There were no significant between-group differences in AEs (55.2% vs. 53.7%), any bleeding (41.8% vs. 46.3%), and major bleeding (9.0% vs. 11.9%) events. Conclusions: Apixaban significantly reduced hepatic decompensation events without increasing hemorrhagic episodes in Child-Pugh B7-C10 cirrhosis (CTRI/2023/09/058018).

Hepatology CommunicationsVol. 10(12)
Institute of Genomics and Integrative Biology (IN), Indian Council of Medical Research (IN), All India Institute of Medical Sciences (IN)
Liver Disease and Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon